Swiss Life Asset Management Ltd Reduces Holdings in CVS Health Corporation $CVS

Swiss Life Asset Management Ltd decreased its position in CVS Health Corporation (NYSE:CVS) by 36.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 371,544 shares of the pharmacy operator’s stock after selling 213,343 shares during the period. Swiss Life Asset Management Ltd’s holdings in CVS Health were worth $29,486,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of CVS Health in the 4th quarter valued at approximately $527,000. Pure Financial Advisors LLC boosted its position in shares of CVS Health by 5.7% during the 4th quarter. Pure Financial Advisors LLC now owns 6,986 shares of the pharmacy operator’s stock worth $554,000 after purchasing an additional 377 shares during the period. Income Insurance Ltd purchased a new position in shares of CVS Health during the 4th quarter worth approximately $298,000. Bryn Mawr Trust Advisors LLC boosted its position in shares of CVS Health by 9.6% during the 4th quarter. Bryn Mawr Trust Advisors LLC now owns 3,867 shares of the pharmacy operator’s stock worth $307,000 after purchasing an additional 339 shares during the period. Finally, Dogwood Wealth Management LLC boosted its position in shares of CVS Health by 93.7% during the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 179 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is currently owned by company insiders.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: TD Cowen raised its price target on CVS Health to $110 from $105 and reiterated a buy rating, signaling confidence in further upside after the company’s earnings beat and improved outlook. TD Cowen adjusts price target on CVS Health to 110 from 105
• Positive Sentiment: Recent coverage highlights CVS as a potentially undervalued stock, pointing to strong Q1 revenue growth, higher EPS, and improving margins/medical benefit ratio as signs that fundamentals are strengthening. CVS Health: Still Cheap And Signs Of Improvement
• Positive Sentiment: Commentary from CNBC’s “Final Trades” and other market chatter suggests CVS remains a favored healthcare name among some investors, adding to the bullish tone. Nvidia, CVS Health, Vertiv and an energy stock on CNBC’s Final Trades
• Neutral Sentiment: An executive stock sale by EVP Tilak Mandadi was disclosed, with 69,551 shares sold at an average price of $89.58. While insider selling can draw attention, the transaction appears more likely to be viewed as portfolio-related than a fundamental red flag. SEC Form 4 filing
• Neutral Sentiment: Additional articles this weekend argued CVS looks like a strong value stock and could benefit from broader healthcare policy trends, reinforcing the current bullish narrative but without new company-specific catalysts. Here’s Why CVS Health (CVS) is a Strong Value Stock

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Barclays increased their price objective on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft increased their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a research report on Friday. Bank of America lowered their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Finally, DA Davidson increased their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and an average target price of $96.12.

CVS Health Price Performance

CVS Health stock opened at $92.22 on Tuesday. The firm has a market cap of $117.67 billion, a PE ratio of 40.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $92.77. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average is $77.43 and its two-hundred day moving average is $78.15.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts expect that CVS Health Corporation will post 7.48 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s dividend payout ratio is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.